GlassScriptPhysician profile
Kelsey Real Kennedy
NPI 1194222844
$6,329.79
in general payments reported to CMS, 2019-2025
29 companies · $2,092 in 2025
The $2,092 reported for 2025 was more than what 77% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $346 · 2021: $551 · 2022: $918 · 2023: $558 · 2024: $1,044 · 2025: $2,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,693.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,564.68 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $614.15 | 2019-2025 | |
| Janssen Biotech, INC. | $543.02 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Genzyme Corporation | $360.95 | 2020-2025 | |
| Galderma Laboratories, L.P. | $339.10 | 2019-2025 | Nemluvio |
| Lilly USA, LLC | $281.10 | 2019-2025 | Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $253.94 | 2019-2025 | Dupixent |
| Novo Nordisk INC | $250.17 | 2024-2025 | Ozempic, Rivfloza, Rybelsus |
| Celgene Corporation | $249.98 | 2019 | |
| Dermavant Sciences, INC. | $218.11 | 2023-2024 | Vtama |
| Amgen INC. | $187.07 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $185.01 | 2022-2025 | Opzelura, Opzelura |
| Leo Pharma INC. | $166.37 | 2025 | Adbry, Anzupgo |
| Arcutis Biotherapeutics, INC. | $161.74 | 2024-2025 | Zoryve |
| Pfizer INC. | $150.18 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $133.51 | 2024-2025 | Bimzelx |
| Journey Medical Corporation | $116.44 | 2025 | |
| Mayne Pharma Commercial LLC | $113.53 | 2025 | |
| Sun Pharmaceutical Industries INC. | $113.11 | 2021-2025 | |
| Kerecis Limited | $78.45 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $52.44 | 2024-2025 | Cabtreo |
| Organon LLC | $50.07 | 2025 | |
| Organogenesis INC. | $47.00 | 2025 | Affinity |
| Kyowa Kirin, INC. | $22.74 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $17.65 | 2023 | Valchlor |
| Paratek Pharmaceuticals, INC. | $16.90 | 2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.49 | 2025 | Spevigo |
| Biofrontera INC. | $13.67 | 2025 | Ameluz |
| Smith+Nephew, INC. | $12.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Kennedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.